成纤维细胞生长因子-23与心血管及非心血管疾病风险的荟萃分析
该荟萃分析纳入多个前瞻性队列,比较基线FGF-23浓度最高三分位与最低三分位,汇总心肌梗死、卒中、心力衰竭、心血管死亡和全因死亡的相对风险,发现FGF-23与心血管及非心血管结局的关联强度相似且无暴露-反应关系,提示关联可能非因果。
要点
- FGF-23最高三分位与心肌梗死、卒中、心衰、心血管死亡和全因死亡风险均升高相关。
- 非心血管死亡风险也升高,且关联强度与心血管结局相似。
- 按FGF-23浓度差异排序研究未见风险比趋势,提示可能非因果。
核心结论
- FGF-23升高与心血管及非心血管结局的关联强度相似,且无暴露-反应关系,提示FGF-23与心血管疾病风险的关系可能非因果。
研究设计与样本
- 荟萃分析纳入报告FGF-23浓度与心血管事件风险关联的前瞻性研究,提取最大调整风险比,按基线FGF-23最高三分位与最低三分位比较并汇总结果。
主要发现
- 最高三分位与最低三分位比较,心肌梗死汇总RR为1.33(95%CI 1.12-1.58)。
- 卒中汇总RR为1.26(95%CI 1.13-1.41),心力衰竭为1.48(95%CI 1.29-1.69)。
- 心血管死亡汇总RR为1.42(95%CI 1.27-1.60),全因死亡为1.70(95%CI 1.52-1.91)。
- 间接计算的非心血管死亡汇总RR为1.52(95%CI 1.28-1.79)。
- 按研究间FGF-23浓度平均差异排序,风险比无趋势。
关键数值与推荐
- 17个一般人群队列中,FGF-23中位浓度因检测方法不同为43-74 RU/ml和38-47 pg/ml。
- 9个非透析CKD队列中,FGF-23中位浓度为102-392 RU/ml。
- 8个透析队列中,FGF-23中位浓度为79-4212 RU/ml和2526-5555 pg/ml。
临床怎么用
- FGF-23升高可提示心血管及非心血管死亡风险增加,但现有证据不支持其作为因果干预靶点。
- 临床解读FGF-23水平时需注意不同检测方法和人群的浓度差异。
局限性
- 非心血管死亡风险比为间接计算所得。
- 各研究间FGF-23浓度差异与风险比无趋势,提示可能存在残余混杂或非因果关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD.Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjusted risk ratios (RRs) were extracted for each outcome and scaled to a comparison of the top versus bottom third of the baseline FGF-23 concentration, and the results aggregated.Results Depending on the assay used, median FGF-23 concentrations were 43-74 RU/ml and 38-47 pg/ml in 17 general population cohorts; 102-392 RU/ml in nine cohorts of patients with CKD not requiring dialysis; and 79-4212 RU/ml and 2526-5555 pg/ml in eight cohorts of patients on dialysis. Overall, comparing participants in the top and bottom FGF-23 concentration thirds, the summary RRs (95% confidence intervals [95% CIs]) were 1.33 (1.12 to 1.58) for myocardial infarction, 1.26 (1.13 to 1.41) for stroke, 1.48 (1.29 to 1.69) for heart failure, 1.42 (1.27 to 1.60) for cardiovascular mortality, and 1.70 (1.52 to 1.91) for all-cause mortality. The summary RR for noncardiovascular mortality, calculated indirectly, was 1.52 (95% CI, 1.28 to 1.79). When studies were ordered by average differences in FGF-23 concentration between the top and bottom thirds, there was no trend in RRs across the studies.Conclusions The similarly-sized associations between increased FGF-23 concentration and cardiovascular (atherosclerotic and nonatherosclerotic) and noncardiovascular outcomes, together with the absence of any exposure-response relationship, suggest that the relationship between FGF-23 and cardiovascular disease risk may be noncausal.
引用
- Marthi A, Donovan K, Haynes R, et al. Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. J Am Soc Nephrol. 2018. PMID: 29764921. doi:10.1681/ASN.2017121334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。